Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
One concern I've had for some time now is ....what prevents a person from simply wiping some form of transparent coating on their finger tips (then let it dry) to block the alcohol sensing? I emailed the company with this question 6 weeks ago and they ignored my email inquiry. Thought?
Thanks for that information! So, how how do you feel that SOBR differentiating its product from those competitors?
UPC has some great upside potential after the recent pull back to 90 cents. Company has a positive EPS, low PE, low O/S, low float.
A bullish research paper published today....
https://finance.yahoo.com/news/goldman-small-cap-research-publishes-125500162.html
It's important to point out though that they were compensated $4K to produce the report.
I noticed this on the YF board. Assessment by the "Valuation Lab"
I like this Valuation Lab observation: "Relief is developing a diversified product portfolio in rare metabolic, pulmonary, and connective tissue disorders, all with high margins. The recent US launch of PKU GOLIKE and the approval and future launch of ACER-001 should provide a boost to short and medium-term revenues. The successful development of RLF-100 in rare pulmonary disorders such as pulmonary sarcoidosis and acute respiratory distress syndrome (ARDS), RLF-TD011 in epidermolysis bullosa (EB), and RLF-OD032 in PKU should boost medium and long-term revenues substantially."
I 100% agree. He can change his mind at any time. The R/S is the biggest risk with this thing IMO. For that reason I do not have all that much skin in the game here.
I agree with that assessment. eom
True, but you will also find almost ZERO CEOs who will publicly state that an R/S will never happen on their watch. It's in the public records.
This is a 3-10 year investment. I ignore the small price swings. After all this is a sub-penny stock. The only real risk is the R/S, which the CEO declares will never happen under his watch. However, what happens if the CEO leaves (retirement, death, sells out, etc). All bets are off on that R/S risk then. JMHO
While your thinking is good intentioned, I can assure you the lawyers will explore the 'deep pockets' of QNTA and will politely say 'no'. QNTA simply has no $$ to pay any lawyer fees, even if they win in court. This is the problem with suing penny stocks. The insiders know upfront that they won't be sued for these very reasons.
Even if the SH coughed up the $$ to pay the lawyers....there are no $$ to win in the courts (QNTA is broke). Jail time would only occur if the lawyers can PROVE fraud, and that will not be easy to do. Remember - Innocent until proven guilty!
And where will you find the $$$ to pay that new CEO? From the company profits?
In the field of law they call it "Deep Pockets". QNTA has no $$$ to pay those lawyers to fight for us.... assuming you/we win the court battle. You will not find a lawyer to work for you unless you pay them 'up front'. Lawyers want to be paid for their services rendered. Period.
Shoondale...so what is your plan? How are you going to influence/shape the outcome? What's your secret? What's your plan?
Last year my predictions were that we won't hear anything of material value (regarding EUA) until summer 2023. With this whole Type C related meeting regarding revising protocol endpoints, summer 2023 may be too optimistic. Assuming the new endpoints are approved, if the FDA requires an extension of the Phase 3 trial then we are looking at EOY. Once the trial is officially complete it will take them 60-90 days to gather/compile/analyze the data and to format it all into an EUA application. Then add another 3-6 months for the FDA to make a decision. I don't think the pps will hold up that long considering Delta Covid is behind us (China is a communist nation outlier).
Now hospitals are typically talking flu, RSV and covid in the same breath. For the most part, covid is turning into just another flu-like virus. I just had COVID and the paxlovid pill knocked it out in less than 48 hours (and I'm in the high risk group).
EUA is designed for 'emergency use', so the FDA now has tightened up approval requirements. Covid SOC today is dramatically better than what it was 2 years ago. China is an exception because they are a communist closed-door country who hides everything they do from the ROW. They do not represent the norm. JMHO
Unfortunately, it doesn't work that way. SH have no (zero) influence over that. It's just wishful thinking. All we can really do is HOPE that Arthur is sincere and has the capability to execute the initiatives he laid out in the last PR. So for now.... We Wait and Wait. Best to put this on the back burner and give it time to work out. It may take all of 2023. Meanwhile, there are other penny stocks to play with that have shorter term promise.
Flagged it ? I have no idea what you are referring to.
May 2023 bring new and great tidings...
https://finance.yahoo.com/news/quanta-medolife-rx-updates-activities-171200121.html
Patience is a Virtue! ACER just won FDA approval on ACER-001, which will generate a new revenue stream for RLFTF.
**
The companies will split net profits from Acer’s territories 60%:40% in favor of Relief. In addition, Relief has licensed the rights for the rest of the world, where Acer will receive from Relief a 15% royalty on all revenues received in Relief’s territories. Acer may also receive a total of $6 million in development milestone payments following the first European (EU) marketing approvals for UCDs and MSUD.
panton...Let's hope that somebody at RLFTF knows something about generating revenues! Thus far they have been very good at dilution by dumping shares on the open market to pay their salaries. Now they have no excuse for not putting the sales people to work to try and sell a product. US launch of Olpruva (ACER-001) in UCDs (early 2023)
Another issue that I have relates to RAM diluting by dumping (selling) ADRs. When that starts to happen in a large way (which I'm sure it will), then it would seem to me that the dilution on the EPS ratio at the ADR level will directly impact the EPS ratio on the underlying RLFTF OTC shares. So dilution in one effectively dilutes the other on the balance sheets. I think RAM is simply using smoke and mirrors, and his longer term goal is to raise cash by dilution of ADRs. Why he hasn't been able to persuade the board to r/s RLFTF puzzles me. Possibly GEM vetoed the r/s as an option. Too bad that we don't have a bionic fly sitting on the wall during the board meetings.
panton.. i've read this before. But the problem is that item 1 on your list only refers to RLF shares on the Swiss. It does not refer to the RLFTF on the OTC. I have a strong feeling that after the ADRs get uplisted to the NASDAQ that the RLFTF shares on the OTC will be dead wood (not tradable), unless I proactively convert my shares. I'm going to make more phone calls next week. This week it seems everyone is out of the office for the holidays.
I have three questions I'm trying to get answered (for those own RLFTF on the OTC):
1) will there be a forced conversion to ADRs on us?
2) will there be a point in time whereby if we don't convert that we will not be able to trade our OTC shares
3) what impact will the ADR conversion (1 for 200 reverse split) have on the underlying 'unconverted' OTC shares?
I haven't been able to find any information on this topic as it relates to SH who own RLFTF shares on the OTC. Have you? I've tried reaching JP Morgan, and no one picks up the phone.
Acer wins FDA OK for Olpruva to treat urea cycle disorders
Dec. 23, 2022 2:30 PM ETAcer Therapeutics Inc. (ACER), RLFTF, RLFTYBy: Dulan Lokuwithana, SA News Editor
Headquarters of US Food and Drug Administration (FDA)
Grandbrothers/iStock Editorial via Getty Images
The U.S. Food and Drug Administration (FDA) has greenlighted Olpruva, being developed by Acer Therapeutics (NASDAQ:ACER) and Swiss biotech Relief Therapeutics (OTCQB:RLFTF) (OTCQB:RLFTY) as a treatment for patients with urea cycle disorders (UCD).
The oral treatment, also known as sodium phenylbutyrate, will therefore be indicated in the U.S. as an adjunctive therapy to the standard of care for chronic management of adults and children with UCDs.
UCDs are a genetically-driven group of diseases that impact the urea cycle, leading to excess accumulation of blood ammonia, which can result in lethargy, coma, multi-organ failure, seizures, and psychiatric symptoms.
In June 2022, the FDA rejected the therapy citing the need for an adequate review of Acer's (ACER) third-party contract manufacturer for the drug, then known as ACER-001.
However, the following month, FDA accepted the company's resubmitted New Drug Application for ACER-001, issuing Jan. 15, 2023, as the target action date.
In August, Acer (ACER) and Relief (OTCQB:RLFTF) announced the European orphan medicinal product designation for ACER-001 as a treatment for the rare metabolic disorder Maple Syrup Urine Disease.
Acer wins FDA OK for Olpruva to treat urea cycle disorders
Dec. 23, 2022 2:30 PM ETAcer Therapeutics Inc. (ACER), RLFTF, RLFTYBy: Dulan Lokuwithana, SA News Editor
Headquarters of US Food and Drug Administration (FDA)
Grandbrothers/iStock Editorial via Getty Images
The U.S. Food and Drug Administration (FDA) has greenlighted Olpruva, being developed by Acer Therapeutics (NASDAQ:ACER) and Swiss biotech Relief Therapeutics (OTCQB:RLFTF) (OTCQB:RLFTY) as a treatment for patients with urea cycle disorders (UCD).
The oral treatment, also known as sodium phenylbutyrate, will therefore be indicated in the U.S. as an adjunctive therapy to the standard of care for chronic management of adults and children with UCDs.
UCDs are a genetically-driven group of diseases that impact the urea cycle, leading to excess accumulation of blood ammonia, which can result in lethargy, coma, multi-organ failure, seizures, and psychiatric symptoms.
In June 2022, the FDA rejected the therapy citing the need for an adequate review of Acer's (ACER) third-party contract manufacturer for the drug, then known as ACER-001.
However, the following month, FDA accepted the company's resubmitted New Drug Application for ACER-001, issuing Jan. 15, 2023, as the target action date.
In August, Acer (ACER) and Relief (OTCQB:RLFTF) announced the European orphan medicinal product designation for ACER-001 as a treatment for the rare metabolic disorder Maple Syrup Urine Disease.
Acer wins FDA OK for Olpruva to treat urea cycle disorders
Dec. 23, 2022 2:30 PM ETAcer Therapeutics Inc. (ACER), RLFTF, RLFTYBy: Dulan Lokuwithana, SA News Editor
Headquarters of US Food and Drug Administration (FDA)
Grandbrothers/iStock Editorial via Getty Images
The U.S. Food and Drug Administration (FDA) has greenlighted Olpruva, being developed by Acer Therapeutics (NASDAQ:ACER) and Swiss biotech Relief Therapeutics (OTCQB:RLFTF) (OTCQB:RLFTY) as a treatment for patients with urea cycle disorders (UCD).
The oral treatment, also known as sodium phenylbutyrate, will therefore be indicated in the U.S. as an adjunctive therapy to the standard of care for chronic management of adults and children with UCDs.
UCDs are a genetically-driven group of diseases that impact the urea cycle, leading to excess accumulation of blood ammonia, which can result in lethargy, coma, multi-organ failure, seizures, and psychiatric symptoms.
In June 2022, the FDA rejected the therapy citing the need for an adequate review of Acer's (ACER) third-party contract manufacturer for the drug, then known as ACER-001.
However, the following month, FDA accepted the company's resubmitted New Drug Application for ACER-001, issuing Jan. 15, 2023, as the target action date.
In August, Acer (ACER) and Relief (OTCQB:RLFTF) announced the European orphan medicinal product designation for ACER-001 as a treatment for the rare metabolic disorder Maple Syrup Urine Disease.
That will never happen. The SEC does not have the resources to go after little fries like QNTA. Their motto with little penny stocks is.... 'Buyer Beware'. 99% of the time, that's as far as they go with it. And the CEO's of tiny sub-penny stocks know it, so they play the odds and almost always win. All we can do is diversity, and use stops for protection.
This is encouraging.....RLFTF will receive profits from this drug if it is approved.
https://industrytrend.net/2022/acer-acer-therapeutics-acer-001-to-be-approved-by-fda/
Yes, take profits to recapture one's initial investment, then hold on to the rest for the ride into the unknown. That's another great 'exit' strategy. Often traders do not have an exit strategy up front. It's critical to have one, otherwise .... later, emotions start influencing the trading behavior. The key is to have rules and the discipline to trade by them (with little emotion). JMHO
Yes, and when / if the longs are sitting in a situation where this pps pops to a buck or two from optimism, pump and hype, then they will have to make the tough decisions!!
Hold on for more paper profits while the analysts keeping pumping/forecasting that the price will go higher (FOMO), OR start cashing out before the final FDA results are in.
Those types of situations really put the emotions and nerves to the ultimate test.
Conventional wisdom suggests that when such a large pps pop occurs, 50% of the chips should be taken off the table (take profits), then let the rest of the chips run where they may. That's how I play the game now.
nosbir.. I purchased a penny stock for 9 cents MANY years ago (CDIK). Within 90 days it went to $4 while on the verge of FDA approval!! I foolishly held as analysts predicted $8. I then watched it fall to a nickel over a period of several months. My lessons learned? Not to be greedy, and have the wisdom and courage to take profits.
Well, it looks like the case between RLFTF and NRX is over. I'm assuming that now the IP and trial data will be handed over to RLTF. But Dr JJ is not yet off the hook!
https://investorshub.advfn.com/uimage/uploads/2022/12/19/ixjytRLFTF_Case_Update.jpg
I emailed the company with that question twice over the past several weeks ago, and nobody replied. It's a simple question, and they are avoiding it. It seems like it would be pretty easy to thwart the security by putting a thin coat of just about anything transparent on your finger tips. This question is also not addressed anywhere in any of their sales literature. Security is a very important issue here, and they are not being transparent about it.
rick....what makes you so sure that revive won't plunge as well if the rejects their EUA. One needs a reality check here. As least for relief they have a broader pipeline of drugs as a backup.
Giovanni...I had to go look that up.
https://www.urbandictionary.com/define.php?term=poly-tick
Giovanni.. so the FDA is grossly understaffed. Then why in the world is the administration sending 55 Billion dollars to Africa in aid over the next 3 years. A large chunk of that should first go to the FDA to help them get life saving drugs out to human beings.
Giov.. I've posted many times that I feel that FDA needs congressional oversight. Without that there will be corruption with officials 'on the take'. And those PDUFA fees are very lucrative, and they waive a carrot in front of FDA decision makers. There is too much of a cloud of secrecy with the FDA. More transparence is needed.
They will have money if they strike an investment deal. I don't feel that their products are attractive enough (from an ROI perspective) to persuade Big Pharm to invest in them. They have nothing that is FDA approved, so Big Pharm would need to see monster ROI before they would finance that operation. JMHO.